Each month in his online column, Dr Andrade offers practical knowledge, ideas, and tips in psychopharmacology to JCP readers in psychiatric and general medical settings.
reported a patient who was treated with famotidine monotherapy (40 mg/d) for peptic ulcer disease. This patient also had schizophrenia, and the deficit symptoms that were present improved after the initiation of famotidine, worsened when famotidine was withdrawn, and improved again when famotidine was reintroduced. Rosse et al 6 reported that a treatment-resistant patient with chronic undifferentiated schizophrenia also improved dramatically with famotidine (40-100 mg/d) across 10 months of treatment.
In an open-label study, 7 famotidine (40 mg/d) was added to the current antipsychotic regimen of 10 schizophrenia and schizoaffective disorder patients who had responded poorly to drugs. There was a small but statistically significant improvement during famotidine treatment relative to before treatment and after treatment withdrawal. In another open-label study, Whiteford et al 8 administered famotidine (40 mg/d) to 5 patients with chronic schizophrenia. Only 1 of 4 study completers showed improvement. Famotidine did not influence the levels of the concurrent antipsychotic medications.
In a study 9 of 12 treatment-resistant schizophrenia patients, all of whom had significant negative symptoms, famotidine augmentation in the dose of 40 mg/d for 6 weeks or longer resulted in sufficient improvement in negative symptoms for 7 patients to be discharged; benefits were observed within 2-3 weeks of the onset of treatment. Rosenberg et al 10 also reported improvement with famotidine (100 mg/d) after just 3 weeks of augmentation therapy in 19 patients with schizophrenia. Rosse et al 11 administered famotidine (100 mg/d) to 18 patients with schizophrenia or schizoaffective disorder; ongoing neuroleptic medications were continued. After 3 weeks of treatment, there were significant improvements in negative symptoms and overall psychopathology, as well as global ratings. Dannon et al 12 also reported improvement with famotidine augmentation of neuroleptic drugs in 11 schizophrenia patients who received treatment for 4 weeks.
In all reports and studies, famotidine was generally well tolerated. There were, however, a few exceptions. For example, Whiteford et al 8 reported that 1 patient had to be withdrawn because of new-onset aggression.
Famotidine Augmentation in Schizophrenia: Randomized Controlled Trials
Four small randomized controlled trials (RCTs) of famotidine augmentation in schizophrenia have been conducted. Abhari and Mohtasham 13 randomized 38 chronic schizophrenia patients to receive famotidine (40 mg/d) or placebo for 6 weeks. All patients also received haloperidol (20 mg/d). Positive and Negative Syndrome Scale (PANSS) total scores decreased significantly more with famotidine than with placebo, but there was no significant difference in negative symptom outcomes. The full text of this study could not be evaluated because it was not in English.
In the only study of patients who were not medicationrefractory, Poyurovsky et al 14 described a 6-week RCT of famotidine (40 mg/d) versus placebo in 14 olanzapine-treated patients with first-episode schizophrenia. Famotidine did not attenuate olanzapine-related weight gain, nor did it influence treatment response to olanzapine on measures of positive symptoms, negative symptoms, or global severity of illness.
Farzin et al 15 recruited 30 schizophrenia patients who had not responded to at least 2 previous antipsychotic trials. These patients were randomized to receive famotidine (60 mg/d) or placebo for 6 weeks. All patients also received perphenazine (40 mg/d). At the end of the study, mean PANSS total scores dropped by 49% (from 133 to 68) in famotidine-treated patients and by 22% (from 118 to 92) in placebo patients. The advantage for famotidine was also significant for the PANSS general psychopathology measure and for a measure of aggression. Results for other outcomes were not presented and were presumably not significant.
Famotidine was well tolerated in these RCTs, as far as could be judged from the limited adverse effect data that were provided.
A Recent RCT
A very recent RCT 2 received wide publicity in the scientific as well as lay press. The study was a small, 4-week, investigator-initiated trial in which 30 patients with chronic schizophrenia were randomized to receive famotidine (n = 16; 100 mg twice daily) or placebo (n = 14) along with their ongoing antipsychotic medication. The dose of famotidine was carefully chosen on the basis of its known pharmacokinetics, so as to ensure a 50%-80% occupancy of H 2 receptors in the brain during most of the day.
All patients had shown unsatisfactory response to previous and current psychotropic medications, and all required assisted living. The mean age of the sample was about 52 years. The sample was 60% female. Some patients were receiving antipsychotic polytherapy, and 11 (37%) were receiving clozapine. The mean PANSS score was 77.6 at baseline. No patient dropped out after randomization.
After 4 weeks of treatment, the PANSS total score decreased significantly more with famotidine than with placebo (by 11% vs 1%, respectively). Improvement in PANSS general psychopathology and Clinical Global Impressions scale scores was also significantly greater with famotidine than with placebo; the advantage for famotidine over placebo was 13% and 11%, respectively. However, improvement in PANSS positive symptom, PANSS negative symptom, and Scale for Assessment of Negative Symptoms scores did not differ significantly between the 2 groups. Famotidine was well tolerated.
The findings of this study suggest that, in chronic, medication-refractory, positive symptom schizophrenia, 4 weeks of treatment with famotidine (200 mg/d) results in a small (10%) but statistically significant improvement in the overall severity of illness. Table 1 provides a synthesis of the literature on famotidine augmentation of antipsychotic drugs in patients with schizophrenia. A critical appraisal of this literature is presented in Table 2 .
Synthesis and Critical Appraisal
There are some additional matters to be considered. Authors who have studied famotidine augmentation have speculated that the benefits arise from H 2 receptor antagonism. This hypothesis is but natural, given that H 2 antagonism is the principal and possibly sole action of the drug. In support of the H 2 antagonism hypothesis is the recent finding that clozapine is a potent H 2 receptor inverse agonist. 16 However, asenapine is a potent H 2 receptor antagonist, 17 and, unlike clozapine, no especial therapeutic advantage for asenapine has so far been postulated in schizophrenia. Furthermore, tricyclic and nontricyclic antidepressant drugs both block H 2 receptors, 18 which is why these drugs were found effective in peptic ulcer disease. 19, 20 Even alprazolam blocks H 2 receptors. 21 Although these drugs may benefit some patients with schizophrenia, it is generally considered that mechanisms such as monoamine reuptake
Clinical Points
Famotidine is a potent, selective histamine H ■ 2 receptor antagonist that has been investigated as an antipsychotic augmentation agent in treatment-refractory schizophrenia, especially for negative symptoms.
Case reports, open studies, and small randomized ■ controlled trials of famotidine have documented differing improvements in total ratings of psychosis, negative symptoms, general psychopathology, and other measures.
Encouraging results notwithstanding, for theoretical reasons ■ as well as for reasons related to the quality of the evidence, it is premature to seriously consider famotidine as a possible antipsychotic augmentation agent. 5, 6 (pooled N = 2) and 6 small open studies [7] [8] [9] [10] [11] [12] (pooled N = 75) indicated benefits with famotidine augmentation in antipsychotic-refractory schizophrenia. 2. The only randomized controlled trial (RCT) in nonrefractory patients 14 found no benefits with famotidine augmentation. 3. Three RCTs on famotidine augmentation in refractory schizophrenia 2, 13, 15 reported benefits on different outcome measures and to different extents (10%-27% superiority over placebo). 4. Famotidine was very well tolerated in all reports and studies. in nonrefractory patients 14 was too small for the negative results of the study to be considered definitive. 3. Of the remaining 3 RCTs, 2, 13, 15 all with results favoring famotidine augmentation in antipsychotic-refractory schizophrenia, 1 13 could not be evaluated because the full text was not in English. One found that famotidine outperformed placebo by a large margin (27%), 15 and 1 found that famotidine outperformed placebo by only a small margin (10%), 2 which falls well below the threshold of most definitions of treatment response even in refractory schizophrenia. Only 1 RCT 2 presented a sound statistical plan, and no RCT corrected for type I errors arising from multiple testing. 4. There was no consistency in the pattern of benefits, although this could be because all RCTs were underpowered. Whereas the anecdotal data and open studies provided an expectation that famotidine would benefit negative symptoms, no RCT found negative symptom improvement with famotidine to significantly exceed that with placebo. In general, the RCTs found that total psychosis ratings, general psychopathology, and/or global assessment scores improved.
inhibition or muscarinic receptor blockade (rather than H 2 receptor blockade) mediate their therapeutic action. Further, given that antidepressant drugs cross the bloodbrain barrier better than does famotidine, one would expect H 2 receptor blockade in the brain to be better with antidepressants than with famotidine (the subject, however, has not been formally studied); if so, given the demonstrated efficacy of antidepressant augmentation in schizophrenia, 22 the possible role for famotidine augmentation stands diminished.
About a decade ago, 2 studies 23,24 suggested lamotrigine as a possible antipsychotic augmentation agent in atypical antipsychotic-and clozapine-refractory schizophrenia. Whereas benefits were small in both studies, one may argue that in such refractory samples, even small benefits could represent a clinically meaningful reduction in illness burden. Hopes were, however, dashed when 2 large (N = 217 and N = 212), industry-driven RCTs found that lamotrigine augmentation was no better than placebo in schizophrenia patients with stable, residual psychotic symptoms. 25 One wonders whether the famotidine experience will follow the lamotrigine story. For the moment, the safest conclusion is that the use of famotidine as an antipsychotic augmentation agent is emphatically experimental.
